World's Best Scientists 2026 revealed!
Håkan Mellstedt

Håkan Mellstedt

D-Index & Metrics

Immunology

D-Index
82
Citations
21562
World Ranking
1523
National Ranking
28

Medicine

D-Index
83
Citations
22337
World Ranking
15737
National Ranking
287

Overview

Håkan Mellstedt is affiliated with the Karolinska Institute in Sweden and has contributed to the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research spans several subfields including Oncology, Molecular Biology, Immunology, Genetics, and Hematology.

The scientist's main research topics cover Chronic Lymphocytic Leukemia Research, Phagocytosis and Immune Regulation, Chronic Myeloid Leukemia Treatments, Lung Cancer Research Studies, PI3K/AKT/mTOR signaling in cancer, Wnt/β-catenin signaling in development and cancer, and Acute Lymphoblastic Leukemia research.

Recent publications include:

  • Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia, 2020, PubMed
  • Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung, 2021, Cell Death and Disease
  • A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells, 2022, Pharmaceutics
  • A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1+ CLL cells, 2021, eJHaem
  • Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules, 2021, Handbook of experimental pharmacology

Frequent publication venues for the scientist include:

  • Pharmaceutics
  • eJHaem
  • PubMed
  • Cell Death and Disease
  • Journal of Hematology

Regular co-author collaborations feature the following researchers:

  • Mohammad Hojjat-Farsangi
  • Johan Schultz
  • Anders Österborg
  • Thomas Olin
  • Marzia Palma

Best Publications

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

    Jeanette Lundin;Eva Kimby;Magnus Björkholm;Per-Anders Broliden

  • Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

    A. Österborg;M. J. S. Dyer;D. Bunjes;G. A. Pangalis

  • Epithelial cell adhesion molecule expression (CD326) in cancer: A short review

    Carlo Patriarca;Roberto Maria Macchi;Anja K. Marschner;Hakan Mellstedt

  • Decreased Expression of the Signal-transducing ζ Chains in Tumor-infiltrating T-Cells and NK Cells of Patients with Colorectal Carcinoma

    Hiroshi Nakagomi;Max Petersson;Inger Magnusson;Claes Juhlin

  • INTERFERON THERAPY IN MYELOMATOSIS

    H Mellstedt;M Björkholm;B Johansson;A Ahre

  • The challenge of biosimilars.

    Hakan Mellstedt;D. Niederwieser;H. Ludwig

  • CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

    J Lundin;Anders Osterborg;G Brittinger;Derek Crowther

  • Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.

    Anders ÖSterborg;Athanasios S. Fassas;Achilles Anagnostopoulos;Martin J. S. Dyer

  • Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease.

    Masanori Matsuda;Max Petersson;Rodica Lenkei;Jean-Luc Taupin

  • A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

    Davide Bagnara;Matthew S. Kaufman;Matthew S. Kaufman;Matthew S. Kaufman;Carlo Calissano;Sonia Marsilio

  • Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell Responses

    Anders Österborg;Qing Yi;Lotta Henriksson;Jan Fagerberg

  • Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

    Geoff Hale;Peppy Rebello;Lee R. Brettman;Chris Fegan

  • Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells.

    David J. McConkey;Miguel Aguilar-Santelises;Pia Hartzell;Ina Eriksson

  • A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes

    Staffan Paulie;Barbro Ehlin-Henriksson;Håkan Mellstedt;Hannu Koho

  • Inversion of chromosome 14 marks human T-cell chronic lymphocytic leukaemia

    L. Zech;G. Gahrton;L. Hammarström;G. Juliusson

  • Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

    Amir H. DaneshManesh;Eva Mikaelsson;Mahmood Jeddi‐Tehrani;Ali Ahmad Bayat

  • Monoclonal lymphocyte population in human plasma cell myeloma.

    H. Mellstedt;S. Hammarström;G. Holm

  • Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia

    D. Killander;A. Dohlwitz;L. Engstedt;S. Franzén

  • Bcl-2, bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression

    Miguel Aguilar-Santelises;Martín E. Rottenberg;Nongnit Lewin;Håkan Mellstedt

Frequent Co-Authors

Anders Österborg
Anders Österborg Karolinska Institute
Magnus Björkholm
Magnus Björkholm Karolinska University Hospital
Mahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani Avicenna Research Institute
Bo Nilsson
Bo Nilsson Uppsala University
Peter Biberfeld
Peter Biberfeld Karolinska Institute
Mikael Jondal
Mikael Jondal Karolinska Institute
Giuseppe Masucci
Giuseppe Masucci Karolinska Institute
Britta Wahren
Britta Wahren Karolinska Institute
Rolf Kiessling
Rolf Kiessling Karolinska Institute
George Klein
George Klein Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open numerous career doors. Many students pursue accelerated paths such as ABSN programs, and finding absn programs with high acceptance rates can help simplify the admission process while advancing quickly toward nursing roles.

Similarly, those considering foundational nursing careers might explore LPN options. Programs highlighted in lpn programs with easiest admission requirements offer accessible entry points for students aiming to begin clinical work in healthcare settings without prohibitive entry barriers.

For advanced practice, nurse practitioner degrees are highly relevant. Identifying which nurse practitioner program is easiest can be crucial for students seeking programs that balance rigorous curriculum with flexible admission policies and efficient completion timelines.

Additionally, those passionate about mental health can specialize through programs such as the best psychiatric mental health nurse practitioner programs online. These options combine strong clinical placements with convenient online formats, preparing graduates for vital roles in psychiatric care.

Best Scientists Citing Håkan Mellstedt

Trending Scientists

Recently Published Articles